Evidence map›Paper›PMID 38175446›Full record

ArticleJournal of hematopathology2023

Genetic mutation analysis of hereditary spherocytosis in Guangxi Zhuang Autonomous Region.

Xingyuan Chen, Lin Liao, Yangyang Wu, Liqun Xiang, Yumei Qin, Meiling Luo, Faquan Lin

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Journal of hematopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xingyuan ChenKey Laboratory of Clinical Laboratory Medicine of GuangxiDepartment of EducationDepartment of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Lin LiaoKey Laboratory of Clinical Laboratory Medicine of GuangxiDepartment of EducationDepartment of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yangyang WuKey Laboratory of Clinical Laboratory Medicine of GuangxiDepartment of EducationDepartment of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Liqun XiangKey Laboratory of Clinical Laboratory Medicine of GuangxiDepartment of EducationDepartment of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yumei QinKey Laboratory of Clinical Laboratory Medicine of GuangxiDepartment of EducationDepartment of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Meiling LuoKey Laboratory of Clinical Laboratory Medicine of GuangxiDepartment of EducationDepartment of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Faquan LinKey Laboratory of Clinical Laboratory Medicine of GuangxiDepartment of EducationDepartment of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Nanning, China. fqlin1998@163.com.
First Affiliated Hospital of GuangXi Medical University · CNGuangxi Medical University · CN

Funding

Guangxi Zhuang Region Health Department Z20191010National Natural Science Foundation of China 81360263
6 · The paper itself

Abstract

Hereditary spherocytosis (HS) is a common, hereditary hemolytic anemia (HHA) that is attributed to the disturbance of five erythrocyte membrane proteins. HS is also common in Guangxi, China. Target region capture high-throughput sequencing technology was used to analyze genetic mutations found in HS patients. Pedigree analysis was also performed, in some cases, to provide an optimized approach for the etiological diagnosis of complex, hereditary hemolytic anemia. Blood samples from the probands and their families were assessed by laboratory tests, target region capture high-throughput sequencing technology, and Sanger sequencing. We detected 79 HS patients from 37 unrelated families. The mutations observed in these patients were found mainly in four HS-related genes. These included SLC4A1, which was mutated in 31.65% of patients (25/79), SPTA1 (30.78% (24/79)), EPB42 (6.33% (5/79)), and SPTB (5.06% (4/79)). Composite genotype was observed in 26.58% (21/79) of patients and included mutations in two or more HS-related genes or mutations in HS-related genes combined with thalassemia or G6PD deficiency. No significant differences in clinical symptoms were found among patients of various genotypes except total bilirubin. Mean reticulocyte volume (MRV) and mean sphered cell volume (MSCV) of the composite genotype were significantly different from other groups. A total of 28 mutation types were found in HS-related genes. Using high-throughput sequencing technology, we also found some cases that had been misdiagnosed. MRV and MSCV are more significant in compound mutations as sensitive determinants of HS. High-throughput sequencing technology can be used to provide a more effective etiological diagnostic method for HS, with high efficiency and specificity.

Indexed as

Anemia, Hemolytic, CongenitalSpherocytosis, HereditaryChinaGenotypeHumansMutationHemolytic anemiaHereditary spherocytosisPedigree analysisTarget region capture high-throughput sequencing technology

Identifiers

PMID38175446
OpenAlexW4372318107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.